Effects of voriconazole on immunosuppressive concentrations and clinical outcomes in transplant patients

doi:10.19803/j.1672-8629.2022.02.17

Abstract

Abstract: Objective To review the concentrations of immunosuppressants when used with voriconazole and the adverse clinical outcomes caused by voriconazole in order to provide references for safe and rational clinical use of this drug. Methods Domestic and foreign literature about the effect of voriconazole on immunosuppressants as well as the combined dosage recommended in guidelines in different countries were reviewed. Results The effect of voriconazole on immunosuppressants varied widely from individual to individual. The dosage of voriconazole recommended in different instructions and guidelines was not applicable to each patient. Conclusion The combination of voriconazole and immunosuppressants requires individualized administration according to the blood concentration and genetic polymorphisms of enzymes in liver drugs

Key words: voriconazole, immunosuppressant, blood concentration, adverse drug reaction

CLC Number:

R978.5R994.11

CAO Xin, CUI Xiangli. Effects of voriconazole on immunosuppressive concentrations and clinical outcomes in transplant patients[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 193-195.

References

[1] BODRO M, SABE N, GOMILA A, et al.Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients[J]. Transplant Proc, 2012, 44(9): 2682-2685.
[2] PURKINS L, WOOD N, GREENHALGH K, et al.Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety[J]. British Journal Of Clinical Pharmacology, 2003, 56(1): 10-16.
[3] JEONG S, NGUYEN PD, DESTA Z.Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 ( CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and3A[J]. Antimicrobial Agents and Chemotherapy, 2009, 53(2) : 541-551.
[4] LIU ZY, CHEN K, LIU YY, et al.Pharmacokinetic impact of voriconazole on immunosuppressors: a systematic review[J]. Clinical Medication Journal(临床药物治疗杂志), 2016, 14(6): 21-26.
[5] CHAU MM, KONG DCM, HAL VAN SJ, et al.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014[J]. Internal Medicine Journal, 2014, 44(12b): 1364-1388.
[6] PATTERSON TF, THOMPSON GR, DENNING DW, et al.Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis, 2016, 63(4): e1-e60.
[7] CHEN K, ZHANG X, KE X, et al.Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit, 2018, 40(6): 663-674.
[8] LAVERDIERE M, BOW EJ, ROTSTEIN C, et al.Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective[J]. Can J Infect Dis Med Microbiol, 2014, 25(6): 327-343.
[9] ULLMANN AJ, AGUADO JM, ARIKAN-AKDAGLI S, et al.Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect, 2018, 24(Suppl 1): e1-e38.
[10] Voriconazole for injection (Vfend) [EB/OL]. (2016-05-11)[2018-10-08]. http://www.nbdyf.com/yaopinmulu/3429.html.
[11] HAMADA Y, TOKIMATSU I, MIKAMO H, et al.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. Journal of Infection and Chemotherapy: official journal of the Japan Society of Chemotherapy, 2013, 19(3): 381-392.
[12] SHI BY, YUAN M.Guidelines for immunosuppressive therapy for renal transplant recipients in China(2016)[J]. Organ Transplantation(器官移植), 2016, 7(5): 327-331.
[13] ROMERO AJ, LE PP, NILSSON LG, et al.Effect of voriconazole on thepharmacokinetics of cyclosporine in renal transplant patients[J]. Clin Pharmacol Ther, 2002, 71(4): 226-234.
[14] KIKUCHI T, MORI T, YAMANE A, et al.Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation[J]. Clin Transplant, 2012, 26(5): E544-548.
[15] WANG Y, PEI YP, FANG Y, et al.Correlation between blood concentrations of ciclosporin and its adverse drug reactions in immunosuppressive treatment of hematopoietic stem cell transplantation recipients[J]. Pharmaceutical Care and Research(药学服务与研究), 2008, 8(1): 21-23.
[16] VANHOVE T, BOUWSMA H, HILBRANDS L, et al.Determi-nants of the magnitude of interaction between tacrolimus and voriconazole /posaconazole in solid organ recipients[J]. Am J Transplant,2017, 17(9) : 2372-2380.
[17] GROLL AH, TOWNSEND R, DESAI A, et al.Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4[J]. Transpl Infect Dis, 2017, 19(5): e12751.
[18] DAVIS S, GRALLA J, KLEM P, et al.Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation[J].Am J Transplant,2018,18(4) : 907-915.
[19] RAMAN V, SHIMIN Z, TIMOTHY G, et al.Voriconazole Inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes[J]. Antimicrob Agents Chemother, 2002, 46(9) : 3091-3093.
[20] CAPONE D,TARANTINO G,GENTILE A, et al.Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient[J]. Journal of Clinical Pharmacy and Therapeutics, 2010, 35(1) : 121-124.
[21] ZHANG YQ, LI XL, LIN XY, et al.Case analysis of the interaction between voriconazole and tacrolimus in renal transplantation patients[J]. Strait Pharmaceutical Journal(海峡药学), 2018, 30(4): 122-124.
[22] IWAMOTO T, MONMA F, FUJIEDA A, et al.Effect of genetic polymorphism of CYP3A5 and CYP2C19 and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation[J]. Ther Drug Monit, 2015, 37(5) : 581-588.
[23] SADABA B, CAMPANERO MA, QUETGLAS EG, et al.Clinical relevance of sirolimus drug interactions in transplant patients[J]. Transplant Proc, 2004, 36(10): 3226-3228.
[24] MARTY FM, LOWRY CM, CUTLER CS, et al.Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2006, 12(5): 552-559.
[25] SUROWIEC D, DEPESTEL DD, CARVER PL.Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management[J]. Pharmacotherapy, 2008, 28(6): 7197-7229.